Related Experiment Videos
Angiotensin blockade in type 2 diabetic renal disease
Luis Miguel Ruilope1, José Luño
1Unidad de Hipertensión, Hospital 12 de Octubre, Madrid, Spain. Luis_M_Ruilope@teleline.es
Abstract:
The available evidence on renal protection in type 2 diabetes mellitus favors the administration of an angiotensin receptor blocker (ARB) more than that of an angiotensin converting enzyme inhibitor (ACEi). This evidence is based on recent studies showing that losartan and irbesartan can prevent the development of overt diabetic nephropathy in microalbuminuric type 2 diabetic patients as well as slow the velocity of progression to end-stage renal disease in patients with overt type 2 diabetic nephropathy. These studies do not deny the possibility that ACEi are equally effective, but studies of an adequate magnitude are lacking. These findings on ARB administration do not preclude the importance of strict control of blood pressure and proteinuria and/or albuminuria to avoid or retard renal damage in type 2 diabetic patients.
Insights
For type 2 diabetes, angiotensin receptor blockers (ARBs) show greater evidence for renal protection than angiotensin converting enzyme inhibitors (ACEi). ARBs help prevent diabetic nephropathy and slow its progression to end-stage renal disease.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Type 2 diabetes mellitus (T2DM) is a leading cause of chronic kidney disease.
- Diabetic nephropathy is a common and serious complication of T2DM.
- Renal protection strategies are crucial for managing T2DM patients.
Purpose of the Study:
- To evaluate the comparative effectiveness of angiotensin receptor blockers (ARBs) versus angiotensin converting enzyme inhibitors (ACEi) for renal protection in T2DM.
- To assess the role of ARBs in preventing and slowing the progression of diabetic nephropathy.
Main Methods:
- Review of recent studies and available evidence on ARB and ACEi administration in T2DM patients.
- Analysis of clinical outcomes including prevention of overt diabetic nephropathy and progression to end-stage renal disease.
Main Results:
- Evidence favors ARBs over ACEi for renal protection in T2DM.
- Losartan and irbesartan demonstrated efficacy in preventing overt diabetic nephropathy in microalbuminuric patients.
- ARBs were shown to slow progression to end-stage renal disease in patients with established nephropathy.
- Limited large-scale studies exist for ACEi efficacy.
Conclusions:
- ARBs are favored for renal protection in T2DM based on current evidence.
- Strict blood pressure and proteinuria/albuminuria control remain essential alongside ARB therapy.
- Further large-scale studies may be needed to definitively compare ACEi and ARB efficacy.